TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
SEATTLE & NEW YORK, Feb. 19, 2015 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company's management team has selected New York City based PCG Advisory (PCG) as agency of record for Investor, Public, and Social Media Relations. After a competitive process, TapImmune determined PCG presented a team that was best matched for the Company's strategic growth plans. In addition, the PCG team presented strong knowledge of the Company's science and financial goals.
Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "We determined that Jeff Ramson and his team at PCG would be the best overall fit for us. PCG's senior team has strong contacts across key U.S. Capital Markets and extensive experience in Public and Social Media. As we move TapImmune's clinical projects forward, we welcome the team's advisory services. We look forward to a better share of voice on Wall Street and beyond."
Jeff Ramson, Founder and CEO of PCG said, "The team at TapImmune is well positioned for growth. The Company is well positioned to become a leader in immunotherapeutics as they develop treatments for Breast and Ovarian Cancers. We look forward to working together and bringing the TapImmune story to our network of investors, bloggers, journalists, and other key stakeholders."
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious disease. The Company's, peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologiesmay be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.
About PCG Advisory
Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic and tactical digital and social media communications and cutting edge media and public relations for public and privately held companies.
The team at PCG has extensive experience with life sciences and healthcare, high technology, metals and mining, financial services and emerging growth companies from around the globe.
PCG's Capital Markets Advisory Services include overall investor strategy development to increase and leverage investor awareness, visibility and credibility. PCG's Social and Digital Media services include leveraging social and professional digital media sites to effectively and accurately communicate client stories. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail and institutional investors using proprietary techniques, search engine optimization, online marketing, website development and our proprietary and extensive distribution network. PCG's Media and Public Relations services are a strategic and integral component of all Corporate Communications. The media and public relations team works with print, broadcast, online news sites and bloggers to communicate the best client story at the right time. PCG also has the capabilities to assist a company during a merger, acquisition or crisis.
Communicating the client's story accurately and effectively is tantamount to maximizing exposure to its current and potential stakeholders.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1(866)-359-7541
PCG Advisory
Kirin M. Smith
Chief Operations Officer
+1(646)-863-6519
Sean Leous
Chief Communications Officer
+1(646) 863-8998
www.pcgadvisory.com
J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938
SOURCE TapImmune Inc.
Share this article